ArticleIEEE transactions on bio-medical engineering2026
A Multimodal Ultrasound-Driven Approach for Automated Tumor Assessment With B-Mode and Multi-Frequency Harmonic Motion Images.
Article in IEEE transactions on bio-medical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveHarmonic Motion Imaging (HMI) is an ultrasound elasticity imaging method that measures the mechanical properties of tissue using amplitude-modulated acoustic radiation force (AM-ARF). Multi-frequency HMI (MF-HMI) excites tissue at various AM frequencies simultaneously, allowing for image optimization without prior knowledge of inclusion size and stiffness. However, challenges remain in size estimation as inconsistent boundary effects result in different perceived sizes across AM frequencies. Herein, we developed an automated assessment method for tumor and focused ultrasound surgery (FUS) induced lesions using a transformer-based multi-modality neural network, HMINet, and further automated neoadjuvant chemotherapy (NACT) response prediction. HMINet was trained on 380 pairs of MF-HMI and B-mode images of phantoms and in vivo orthotopic breast cancer mice (4T1). Test datasets included phantoms (n = 32), in vivo 4T1 mice (n = 24), breast cancer patients (n = 20), FUS-induced lesions in ex vivo animal tissue and in vivo clinical settings with real-time inference, with average segmentation accuracy (Dice) of 0.91, 0.83, 0.80, and 0.81, respectively. HMINet outperformed state-of-the-art models; we also demonstrated the enhanced robustness of the multi-modality strategy over B-mode-only, both quantitatively through Dice scores and in terms of interpretation using saliency analysis. The contribution of AM frequency based on the number of salient pixels showed that the most significant AM frequencies are 800 and 200 Hz across clinical cases. SIGNIFICANCE: We developed an automated, multimodality ultrasound-based tumor and FUS lesion assessment method, which facilitates the clinical translation of stiffness-based breast cancer treatment response prediction and real-time image-guided FUS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.